Mode
Text Size
Log in / Sign up
N/A N=100

Clinical Follow-up to Evaluate the Clinical Usefulness of Gentamicin-coated Titanium Nails in Tibia Fractures

Tibia Fractures

Enrolled (actual)
100
Serious AEs
38.4%
Results posted
Feb 2015
Primary outcome: Primary: Quality of Life: SF-12 Physical Component Summary (PCS) — 36.9; 41.2; 45.6; 44.6 scores on a scale

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
ETN PROtect (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Synthes GmbH
Primary completion
Oct 2013

Outcome Measures

OutcomeResultp-value
PRIMARY
Quality of Life: SF-12 Physical Component Summary (PCS)
36.9; 41.2; 45.6; 44.6
PRIMARY
Quality of Life: SF-12 Mental Component Summary (MCS)
52.7; 53.2; 53.3; 53.1
PRIMARY
Quality of Life: EQ-5D
0.7; 0.8; 0.8; 0.9
PRIMARY
Functional Outcome: IOWA Ankle Score
86.3; 62.9; 76.4; 81.2; 85.2
PRIMARY
Functional Outcome: WOMAC
29.3; 24.6; 19.2; 18.2
PRIMARY
Infection Adverse Events
6; 5; 0
SECONDARY
Evidence of Anatomic Bone Union According to Johnson Classification
4; 2; 9; 11; 52
SECONDARY
Evidence of Economic Bone Union According to Johnson Classification
3; 19; 8; 8; 40
SECONDARY
Evidence of Functional Bone Union According to Johnson Classification
4; 1; 24; 17; 32
SECONDARY
Surgeon's Perceived Satisfaction
18.2; 18.9; 14.9
SECONDARY
Likelihood to Develop Wound Infection Assessed by Surgeon
19.6; 14.6; 14.4
SECONDARY
Likelihood to Develop a Non-union Assessed by Surgeon
26.4; 23.0; 19.6
SECONDARY
Pain by Visual Analog Scale (VAS)
19.3; 24.3; 27.0; 21.0; 23.0
SECONDARY
Patient's Perceived Satisfaction
63.8
SECONDARY
Time to Full Weight Bearing
90.0

Summary

This post market clinical follow-up is to confirm the clinical usefulness of the Expert Tibial Nail (ETN) PROtect device for operative stabilization in patients with a tibia fracture as measured by the quality of life (EQ5D, SF-12) instruments, disease-specific questionnaires (Iowa Ankle Score, WOMAC) and assessment of (Non-)Device Related Adverse Events or complications.

Eligibility Criteria

Inclusion Criteria

  • Adult patients aged 18 years or more
  • Open or closed tibia fracture according to the surgical technique

Exclusion Criteria

  • Women who are pregnant or breast-feeding or are planning to become pregnant during the study
  • Patients with consumptive/ malignant primary disease and a life expectancy of < 3 months
  • Patients with a known allergy to aminoglycosides
  • Physical or mental incapacity, which makes it impossible to obtain informed consent
  • History of drug and alcohol abuse
  • Patient unlikely to cooperate
  • Legal incompetence
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01282294). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search